Ovarian Cancer: Methods and Protocols by Anastasia MalekOvarian Cancer: Methods and Protocols by Anastasia Malek

Ovarian Cancer: Methods and Protocols

EditorAnastasia Malek, Oleg Tchernitsa

Hardcover | August 3, 2013

Pricing and Purchase Info

$180.95

Earn 905 plum® points

In stock online

Ships free on orders over $25

Not available in stores

about

Ovarian cancer is the most lethal malignancy of the female reproductive system and is also the fifth leading cause of cancer death in women. Sharing common characteristics of cancer, ovarian malignancy possess several clinical and biological particularities  In Ovarian Cancer: Methods and Protocols, expert researchers in the field provide methods that have been created or adapted to study various aspects of ovarian cancer. These methods and techniques are applicable to study genetic alterations present in ovarian cancer, structural and metabolic features of ovarian cancer cells, include  in vitro and in vivo models that recapitulate ovarian cancer development and progression, and describe ovarian cancer-oriented drug delivery approaches. Methodological chapters are grouped into seven thematic parts, any of them is introduced by short subject review. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and key tips on troubleshooting and avoiding known pitfalls.  Authoritative and practical, Ovarian Cancer: Methods and Protocols seeks to aid scientist to optimize study designs, to correctly select the most applicable methods, and to produce interesting and novel results.
Title:Ovarian Cancer: Methods and ProtocolsFormat:HardcoverDimensions:430 pagesPublished:August 3, 2013Publisher:Humana PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:162703546X

ISBN - 13:9781627035460

Look for similar items by category:

Customer Reviews of Ovarian Cancer: Methods and Protocols

Reviews

Table of Contents

Part I: Evaluation of Genomic Alteration 1. Ovarian Cancer GenomeEvgeny N. Imyanitov 2. Identifying Associations Between Genomic Alterations in TumoursJoshy George, Kylie L Gorringe, Gordon K. Smyth, and David DL Bowtell 3. Analysis of Genome-wide DNA Methylation Profiles by BeadChip TechnologyQiong Lin, Wolfgang Wagner, and Martin Zenke 4. Integrative Prediction of Gene Function and Platinum Free Survival from Genomic and Epigenetic Features in Ovarian CancerKazimierz O. Wrzeszczynski, Vinay Varadan, Sitharthan Kamalakaran, Douglas A. Levine, Nevenka Dimitrova, and Robert Lucito 5. Survival Prediction Based on Inherited Gene Variation AnalysisMine S. Cicek, Matthew J. Maurer, and Ellen L. Goode Part II: Targeted Analysis of DNA Methylation6. Main Principles and Outcomes of DNA Methylation Analysis Susan K. Murphy, Christopher F. Bassil, and Zhiqing Huang 7. Methylation-specific PCRZhiqing Huang, Christopher F. Bassil, and Susan K. Murphy 8. Bisulfite Sequencing of Cloned Alleles Zhiqing Huang, Christopher F. Bassil, and Susan K. Murphy 9. Bisulfite Pyrosequencing Christopher F. Bassil, Zhiqing Huang, and Susan K. Murphy Part III: Gene/Genome Expression Assessing10. RNA Networks in Ovarian CancerAnastasia Malek  11. Microarray-based Transcriptome Profiling of Ovarian Cancer CellsJuan Cui, Ying Xu and David Puett 12. Deep Transcriptome Profiling of Ovarian Cancer Cells using Next Generation Sequencing Approach Lisha Li, Jie Liu, Wei Yu, Xiaoyan Lou, Bingding Huang, and Biaoyang Lin 13. Assessment of mRNA Splice Variants by qRT-PCR  Ileabett M. Echevarria Vargas and Pablo E. Vivas-Mejía 14. Micro-RNA Profiling in Ovarian CancerMarilena V. Iorio and Carlo M. Croce 15. Detailed Analysis of Promoter-associated RNASara Napoli 16. Integrating Multiple Types of Data to Identify MicroRNA-gene Co-modulesShihua Zhang  Part IV: Cellular Structure and Metabolism Analysis17. Energy Metabolism and Changes in Cellular Composition in Ovarian CancerAnastasia Malek  18. Metabolomic Profiling of Ovarian Carcinomas using Mass SpectrometryMiranda Y. Fong, Jonathan McDunn, and Sham S. Kakar 19. Choline Metabolic Profiling by Magnetic Resonance Spectroscopy Egidio Iorio, Alessandro Ricci, Maria Elena Pisanu, Marina Bagnoli, Franca Podo, and Silvana Canevari 20. Proteomic Profiling of Ovarian Cancer Models using TMT-LC-MS/MSJohn Sinclair and John F. Timms 21. Characterization of Signalling Pathways by Reverse Phase Protein ArraysKatharina Malinowsky, Claudia Wolff, Christina Schot,t and Karl-Friedrich Becker 22. N-Glycosylation Analysis by HPAEC-PAD and Mass SpectrometrySebastian Kandzia and Júlia Costa  Part V: In Vitro Assays in Ovarian Cancer Research23. In vivo and in vitro Properties of Ovarian Cancer Cells Anastasia Malek   24. Establishement of Primary Cultures from Ovarian Tumour Tissue and Ascites FluidBrigitte L. Thériault, Lise Portelance, Anne-Marie Mes-Masson, and Mark W. Nachtigal25. Ovarian Cancer Stem Cells EnrichmentLijuan Yang and Dongmei Lai 26. Assessment of Resistance to Anoikis in Ovarian CancerXiaoping He, Jeremy Chien, and Viji Shridhar 27. Analysis of EMT by Flow Cytometry and ImmunohistochemistryRobert Strauss, Jiri Bartek, and André Lieber  Part IV: Models of Ovarian Carcinogenesis28. Challenges in Experimental Modeling of Ovarian CancerogenesisJim Petrik 29. Transformation of the Human Ovarian Surface Epithelium with Genetically-defined ElementsWeiwei Shan and Jinsong Liu 30. In vitro Model of Spontaneous Mouse OSE TransformationPaul C. Roberts and Eva M. Schmelz 31. Orthotopic, Syngeneic Mouse Model to Study the Effects of Epithelial-Stromal Interaction James B. Greenaway and Jim J. Petrik 32. Immunocompetent Mouse Model of Ovarian Cancer for in vivo ImagingSelene Nunez-Cruz and Nathalie Scholler  Part VII: Non-Viral drug Delivery System for Ovarian Cancer Therapy33. Drug Delivery Approaches for Ovarian Cancer TherapyAnastasia Malek  34. Polymer-Based Delivery of RNA-Based Therapeutics in Ovarian Cancer Ulrike Weirauch, Daniela Gutsch, Sabrina Höbel, and Achim Aigner 35. Ligand-coupled lipoprotein for ovarian cancer-specific drug deliveryIan R. Corbin 36. Mesoporous Silicon Particles for Sustained Gene SilencingNafis Hasan, Aman Mann, Mauro Ferrari, and Takemi Tanaka 37. Exosomes as a Potential Tool for a Specific delivery of Functional MoleculesIrina Nazarenko, Anne-Kathleen Rupp, and Peter Altevogt